top of page
Medilabo RFP today announced the U.S. Food and Drug Administration (FDA) granted Orphan Drug Designation for ML 1707, a potential therapy for the treatment of Frontotemporal Dementia (FTD). (March 9, 2023)
This important designation is a milestone in the development of ML 1707 and highlights the need for potential new treatment options for patients with FTD.
Medilabo RFP's finding of rifampicin attenuates C9orf72-linked dementia was featured in a News medical (May 23, 2022)
Excellent efficacy of Medilabo RFP's nasal rifampicin and resveratrol combination in neurodegenerative dementia was introduced in Science Daily (Dec 19, 2021)
Medilabo RFP Awarded 2021 "Industry-Academia-Public Forest" promotion project for business facilitation (Oct 1, 2020)
Medilabo RFP's CSO, Dr. Tomiyama was featured in Daily Sincho (Mar 23, 2019)
bottom of page